# Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression

> **NCT05373680** · PHASE2,PHASE3 · COMPLETED · sponsor: **Tanta University** · enrollment: 118 (actual)

## Conditions studied

- Renal Insufficiency, Chronic

## Interventions

- **DRUG:** Metformin
- **DRUG:** Empagliflozin
- **OTHER:** Control

## Key facts

- **NCT ID:** NCT05373680
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2024-04-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2025-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05373680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05373680, "Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05373680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*